YU32502A - Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina - Google Patents

Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina

Info

Publication number
YU32502A
YU32502A YU32502A YUP32502A YU32502A YU 32502 A YU32502 A YU 32502A YU 32502 A YU32502 A YU 32502A YU P32502 A YUP32502 A YU P32502A YU 32502 A YU32502 A YU 32502A
Authority
YU
Yugoslavia
Prior art keywords
imidazolidinone
preparation
intermediates
alpha
integrin antagonists
Prior art date
Application number
YU32502A
Other languages
English (en)
Inventor
Mark S. Jensen
Michael Palucki
Nelo R. Rivera
Kenneth M. Wells
Yi Xiao
Yaling Wang
Chinhua Yang
Nobuyoshi Yasuda
Original Assignee
Merck & Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co.Inc. filed Critical Merck & Co.Inc.
Publication of YU32502A publication Critical patent/YU32502A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Obezbedjen je novi postupak za proizvodnju imidazolidinonskih antagonista ανГџ3/ανГџ5 integrina, a time se dobijaju i korisni intermedijeri. Ova jedinjenja su antagonisti αvГџ/αvГџ5 integrinskih receptora i zbog toga su korisni za inhibisanje resorpcije kosti i lečenje i prevenciju osteoporoze. Takodje, izložena je i 3-2{2-okoso-3-[3-(5,6,7,8-tetrahidro-[1,8]naftiridin-2-il)-propil]imidazolidin-1-il}-3(S)-(6-metoksi-piridin-3-il)-propionska kiselina u obliku hemihidrata.[A novel process is provided for the preparation of imidazolidinone αvГџ3/αvГџ5 integrin antagonists, and the useful intermediates obtained therein. These compounds are antagonists of αvГџ3/αvГџ5 integrin receptors and thus useful for inhibiting bone resorption and treating and preventing osteoporosis. Also disclosed is 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin- 1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid in the form of a hemihydrate.
YU32502A 1999-11-08 2000-11-03 Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina YU32502A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16397999P 1999-11-08 1999-11-08

Publications (1)

Publication Number Publication Date
YU32502A true YU32502A (sh) 2004-12-31

Family

ID=22592461

Family Applications (1)

Application Number Title Priority Date Filing Date
YU32502A YU32502A (sh) 1999-11-08 2000-11-03 Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina

Country Status (20)

Country Link
EP (1) EP1230240B1 (sh)
JP (1) JP2003513974A (sh)
KR (1) KR20020048427A (sh)
CN (1) CN1414966A (sh)
AR (1) AR029407A1 (sh)
AT (1) ATE245645T1 (sh)
AU (1) AU777919B2 (sh)
BR (1) BR0015384A (sh)
CA (1) CA2389999A1 (sh)
CZ (1) CZ20021508A3 (sh)
DE (1) DE60004087T2 (sh)
EA (1) EA200200548A1 (sh)
ES (1) ES2202191T3 (sh)
HU (1) HUP0203246A3 (sh)
IL (1) IL149313A0 (sh)
MX (1) MXPA02004547A (sh)
PL (1) PL355011A1 (sh)
SK (1) SK8012002A3 (sh)
WO (1) WO2001034602A2 (sh)
YU (1) YU32502A (sh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2421792A1 (en) * 2000-09-13 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20040254211A1 (en) 2000-09-14 2004-12-16 Arison Byron H Alpha v integrin receptor antagonists
US6706885B2 (en) 2001-06-06 2004-03-16 Merck & Co., Inc. Process for preparing integrin antagonist intermediates
US6509347B2 (en) 2001-06-11 2003-01-21 Merck & Co., Inc. Crystalline forms of an integrin receptor antagonist
US6646130B2 (en) 2001-07-19 2003-11-11 Merck & Co., Inc. Process to chiral integrin antagonist beta-amino acid intermediate
AR038189A1 (es) * 2002-01-29 2005-01-05 Merck & Co Inc Proceso para la preparacion de intermediarios de antagonistas de integrina
US20060030581A1 (en) * 2002-09-20 2006-02-09 Debusi Laura A Mannitol formulation for integrin receptor antagonist
RS55856B1 (sr) 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
DK3929196T3 (da) 2013-09-24 2023-09-25 Fujifilm Corp Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf
AP2016009156A0 (en) * 2013-10-25 2016-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016054483A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) * 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
CA3042693A1 (en) * 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Pyrrole amides as .alpha.v integrin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003095B1 (ru) * 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов

Also Published As

Publication number Publication date
HUP0203246A3 (en) 2003-12-29
BR0015384A (pt) 2002-10-08
IL149313A0 (en) 2002-11-10
MXPA02004547A (es) 2002-09-02
CZ20021508A3 (cs) 2002-10-16
ATE245645T1 (de) 2003-08-15
DE60004087D1 (de) 2003-08-28
DE60004087T2 (de) 2004-04-15
EP1230240B1 (en) 2003-07-23
SK8012002A3 (en) 2002-10-08
AU1461401A (en) 2001-06-06
JP2003513974A (ja) 2003-04-15
AU777919B2 (en) 2004-11-04
ES2202191T3 (es) 2004-04-01
WO2001034602A3 (en) 2002-01-17
AR029407A1 (es) 2003-06-25
KR20020048427A (ko) 2002-06-22
HUP0203246A2 (hu) 2003-01-28
CA2389999A1 (en) 2001-05-17
CN1414966A (zh) 2003-04-30
EP1230240A2 (en) 2002-08-14
PL355011A1 (en) 2004-03-22
WO2001034602A2 (en) 2001-05-17
EA200200548A1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
YU32502A (sh) Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina
MX9702070A (es) Nuevos inhibidores de resorcion osea y antagonistas de receptor de vitronectina.
HK1036219A1 (en) Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
HUP0104912A1 (hu) Új acil-guanidin-származékok mint csontfelszívódást gátlók és vitronektin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0203560A3 (en) Method for the production of calendic acid, a fatty acid containing delta-8,10,12 conjugated double bonds and dimorphecolic acid, a fatty acid containing a 9-hydroxy group and delta-10,12 conjugated double bonds
IL146313A (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
MX9805253A (es) Antagonistas del receptor de vitronectina.
HK1045805A1 (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
NZ336560A (en) 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists
EP1171135A4 (en) 6-AZAINDOLE COMPOUNDS FOR USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS
CA2225366A1 (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
HU0104085D0 (en) Method for the treatment of pulmonary hypertension
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
BR9815296A (pt) Derivados de ácido carboxìlico 3-pirrolidina e ouso dos mesmos como antagonistas endotelina
HUP0101143A3 (en) Pyridin-carboxylic acid derivatives as vitronectin receptor antagonists, process for producing them and pharmaceutical compositions containing them
GR3036639T3 (en) 5-(4-subst.-piperidinyl-1)-3-aryl-pentanoic acid derivatives as tachykinin receptor antagonist
IL141165A0 (en) New imidazopyridine compounds for the inhibition of acid secretion, pharmaceutical compositions thereof and process for preparing the same
EP1165075A4 (en) 6-AZAINDOLE GONADOLIBERIN ANTAGONIST COMPOUNDS
ZA200004720B (en) Process for preparing 5-hydroxybenzo (B) thiophene-3-carboxylic acid derivatives.
WO2000009537A3 (en) Compounds having growth hormone releasing activity
PE20001563A1 (es) Antagonistas del receptor de vitronectina
AU9621598A (en) Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
EP1165076A4 (en) 6-AZAINDOL COMPOUNDS AS GONADOLIBERINE'S ANTAGONISTS
EP1171126A4 (en) 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists